Phoenix, Arizona--(Newsfile Corp. - January 20, 2021) - The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB: SILO) ("the Company"), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson's, and other rare neurological disorders. CEO of the Company, Eric Weisblum, joined Stock Day host Everett Jolly.
MindMed begins the first Phase 1 clinical trial testing the safety and tolerance of MDMA and LSD in combination.
Entheon announces a new partnership to advance its psychedelic drug R&D.
Cybin's bought deal financing has been upsized to CAD$30 million.
The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.
New research suggests that the public’s perception of the potential harms of magic mushrooms is not in line with drug laws.
Even before Oregon and Washington, D.C., decriminalized medical psilocybin, the active ingredient in “magic mushrooms,” in November, a market was emerging for schools that teach mental and medical health professionals how to use psychedelics in their treatment.
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Several Canadian cannabis company CEOs were among the highest paid corporate executives in the nation in 2019, according to a Centre for Policy Alternatives’ analysis titled “The Golden Cushion: CEO compensation in Canada.”
Local Massachusetts lawmakers on Thursday unanimously approved a resolution to decriminalize a wide range of psychedelics—the latest in a national movement to reform laws on entheogenic plants and fungi.
A federal science agency is inviting labs to participate in a large-scale study to assess their ability to accurately analyze marijuana and hemp samples for their cannabinoid profile and possible contaminants.
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
MindMed's new Chief Development Officer has over a decade of experience leading drug development programs.
